Thomas Shrader
Stock Analyst at BTIG
(3.29)
# 1,066
Out of 5,131 analysts
72
Total ratings
49.23%
Success rate
3.83%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | Maintains: Buy | $72 → $147 | $88.67 | +65.78% | 3 | Jan 7, 2026 | |
| IVVD Invivyd | Reiterates: Buy | $10 | $2.45 | +308.16% | 2 | Dec 23, 2025 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $32 | $17.95 | +78.27% | 3 | Dec 5, 2025 | |
| NRXP NRx Pharmaceuticals | Reiterates: Buy | $25 | $2.22 | +1,026.13% | 1 | Dec 3, 2025 | |
| BHVN Biohaven | Reiterates: Buy | $16 | $11.84 | +35.14% | 5 | Nov 18, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $27 | $16.94 | +59.39% | 1 | Nov 17, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $15 → $16 | $4.75 | +236.84% | 3 | Nov 13, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $85 | $45.84 | +85.43% | 6 | Nov 10, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $9 | $4.13 | +117.92% | 2 | Nov 10, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $39 | $29.42 | +32.56% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.52 | +127.27% | 3 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $23 | $7.53 | +205.44% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.84 | - | 4 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $2.14 | +320.56% | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $14 | $7.00 | +100.00% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $63 | $47.84 | +31.69% | 3 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.47 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.61 | +148.45% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.75 | - | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $8.21 | +2,336.05% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $4.06 | +1,377.83% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $5.56 | +25.90% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.31 | +4,030.92% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.72 | +1,179.07% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.33 | +3,734.59% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $6.46 | +147.68% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.90 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.43 | +109.79% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $185.63 | +86.39% | 3 | Feb 21, 2019 |
Bright Minds Biosciences
Jan 7, 2026
Maintains: Buy
Price Target: $72 → $147
Current: $88.67
Upside: +65.78%
Invivyd
Dec 23, 2025
Reiterates: Buy
Price Target: $10
Current: $2.45
Upside: +308.16%
Denali Therapeutics
Dec 5, 2025
Reiterates: Buy
Price Target: $32
Current: $17.95
Upside: +78.27%
NRx Pharmaceuticals
Dec 3, 2025
Reiterates: Buy
Price Target: $25
Current: $2.22
Upside: +1,026.13%
Biohaven
Nov 18, 2025
Reiterates: Buy
Price Target: $16
Current: $11.84
Upside: +35.14%
Alto Neuroscience
Nov 17, 2025
Initiates: Buy
Price Target: $27
Current: $16.94
Upside: +59.39%
Coya Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $4.75
Upside: +236.84%
Vaxcyte
Nov 10, 2025
Reiterates: Buy
Price Target: $85
Current: $45.84
Upside: +85.43%
Aldeyra Therapeutics
Nov 10, 2025
Reiterates: Buy
Price Target: $9
Current: $4.13
Upside: +117.92%
Stoke Therapeutics
Nov 5, 2025
Reiterates: Buy
Price Target: $39
Current: $29.42
Upside: +32.56%
Nov 4, 2025
Reiterates: Buy
Price Target: $8
Current: $3.52
Upside: +127.27%
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $7.53
Upside: +205.44%
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.84
Upside: -
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $2.14
Upside: +320.56%
Oct 13, 2025
Maintains: Buy
Price Target: $7 → $14
Current: $7.00
Upside: +100.00%
Sep 29, 2025
Reiterates: Buy
Price Target: $63
Current: $47.84
Upside: +31.69%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.47
Upside: -
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.61
Upside: +148.45%
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.75
Upside: -
Oct 3, 2023
Initiates: Buy
Price Target: $200
Current: $8.21
Upside: +2,336.05%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $4.06
Upside: +1,377.83%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $5.56
Upside: +25.90%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.31
Upside: +4,030.92%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.72
Upside: +1,179.07%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.33
Upside: +3,734.59%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $6.46
Upside: +147.68%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.90
Upside: -
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.43
Upside: +109.79%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $185.63
Upside: +86.39%